Agenus is proud to unveil the latest research from our investigational botensilimab programs – Agenus

Agenus shared a post on LinkedIn:

“Agenus is proud to unveil the latest research from our investigational botensilimab programs, showcasing significant advancements across our colorectal, pancreatic, lung, melanoma, and sarcoma studies. The data underscore botensilimab’s versatile potential in cold and treatment-resistant solid tumors, including the opportunity to expand into early-stage cancers supported by compelling outcomes in neoadjuvant colorectal cancer.

A live webcast will be hosted at 1:00 p.m. EDT to discuss these results. Learn more here.”

Source: Agenus/LinkedIn